Loading...
•
Dec 31, 2022
Castle Biosciences Q4 2022 Earnings Report
Reported a 53% increase in revenue and a 53% increase in total test reports delivered compared to the same period in 2021.
Key Takeaways
Castle Biosciences reported strong fourth-quarter results with a 53% increase in revenue to $38.3 million and a 53% increase in total test reports delivered. The company anticipates generating between $170-180 million in total revenue in 2023.
Revenues were $38.3 million, a 53% increase compared to $25.0 million during the same period in 2021.
Delivered 12,644 total test reports in the fourth quarter of 2022, an increase of 53% compared to 8,269 in the same period of 2021.
Gross margin for the quarter ended Dec. 31, 2022, was 69%, and adjusted gross margin was 75%.
Net loss for the fourth quarter was $(20.6) million, compared to $(6.4) million for the same period in 2021.
Forward Guidance
The Company anticipates generating between $170-180 million in total revenue in 2023.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...